Overview
- A biomarker analysis published in Nature Biotechnology on Sept. 7 found that rentosertib reduced predicted biological age on six different aging clocks in about 42 trial participants.
- The drug was designed by Insilico Medicine’s AI platforms to inhibit TNIK, a kinase linked to fibrosis and the harmful signaling of senescent cells called the SASP.
- Earlier Phase IIa data published in June 2025 showed a mean 98.4 mL improvement in forced vital capacity at a 60 mg dose in patients with idiopathic pulmonary fibrosis, outcomes that motivated a larger study.
- A randomized, double-blind, placebo-controlled Phase III trial with roughly 320 patients at 47 centers in China began on July 7, 2026 and is expected to provide clinical efficacy and safety answers over the coming years.
- Experts caution the biomarker findings are preliminary because the substudy was small, aging clocks vary in what they measure and may not predict long-term benefit, and the signals may reflect improved lung health rather than generalized anti‑aging effects.